Get started

OWCP

VDRM FULL DD PACKAGEALL THE DD ON VDRM YOU NEED RIGHT HERE (repost) 2dollarbill Saturday, 08/19/17 10:19:12 AM Re: None Post # 26410 of 26411 Go ALL THE DD ON VDRM YOU NEED RIGHT HERE FDA approved products that ViaDerma (VDRM) offers: -skin cancer therapies (Cantrile) -stem cell therapy product (TetraStem Plus) -topical antibiotics (TetraStem the world’s strongest broad-spectrum topical antibiotic available) -TETRA-STEM – a tetracycline hydrochloride ointment. An award-winning antibiotic/wound healing product that kills all knows bacteria, including "flesh-eating" bacteria. Tertra-stem also can be used to treat wounds, ulcers -topical anti-viral product (Viralcur) for genital herpes anti-fungal products for onychomycocis (OnyPro) -hair loss prevention product (HairGain) -ACNECLIR/ACNEEN – a salicylic acid based lotion that treats acne -ECODERM – a colloidal oatmeal lotion for Eczema -ACNECYCLINE – a tetracycline hydrochloride ointment that treats acne -DERMONEEN – a salicylic acid lotion used to treat Psoriasis -IVYMED – a zinc acetate based liquid that treats Poison Ivy rashes - STAPHWASH PLUS – a zinc acetate based liquid. This is a non-antibiotic skin cleanser that kills MRSA -TETRA-ABC – a tetracycline hydrochloride based ointment. This is an oil based topical antibiotic that kills all known bacterial infections. A water based version of this product is also available. -STINGMED – a zinc acetate based liquid that treats most insect and spider bites -ADVANCED JELLYFISH STING KIT – a zinc acetate powder, for suspension, that treats Jellyfish stings -VENOMX – a zinc acetate based liquid used topically to treat snake bites. -Product for treatment of Migraines presently; with a future of possibly ( inflammation of fibromyalgia, Cohn’s disease, nicotine addiction, schizophrenia, and pain management for Multiple Sclerosis and cancer. utilizing (CBD's) Calanoids and (THC) Tetrahydrocannabinol biotechs trade at 30x earnings or 5x gross sales or 15x net sales or on air if they are a r and d company, with VDRM we have sales coming this year here is the analysis broken down below ie...from the 500,000 bottles alone will yield $62.5M gross sales $62.5m in gross sales X 5x gross sales = 325m market cap = $1.00 - $1.50 target OR 62.5m in gross sales @ a 50% margin = $31m in net sales X 15x net sales = 450m market cap = $2.00 + target OR 62.5m in gross sales with a $31m in net sales which divided by outstanding stock = 0.15 cents earnings X 30x earnings (pe - price to earnings) = $4.50 + target Lead Product TetraStem World’s strongest broad spectrum tetracycline-based topical antibiotic with proven results. Used for cuts, scrapes, wounds, infections, burns, acne, psoriasis, eczema, and minor injuries. Very low water content and optimum (low) viscosity. Uses both a chemical AND physical kill mechanism which is advantageous over traditional antibiotics which use only a chemical kill mechanism and has a better resistance profile. Potential Markets ViaDerma is developing products in many fields of use, including: Topical antibiotics- $6 billion/year Toenail antifungal drugs- $3 billion/year Diabetic amputations- $3 billion/year Global acne- $3.02 billion/year Psoriasis- $7.3 billion/year Eczema- $2.5 billion/year Other potential markets include burns, anti-aging/wrinkle remover cream, medical cannabis, male-pattern baldness, skin cancer, erectile dysfunction, and pain management. Innovative, patent pending dual carrier transdermal technology which can transformoral medication into topical products. Ability to enable active ingredients with a rapid transport direct to the site of action. Ability to be used in any field including Sports Nutrition Supplements, Cosmetics, First Aid Products, Wound Care, and Skin Diseases like Acne, Eczema, and Psoriasis. Dual carrier liquid which can possess life enhancing technology with up to four year shelf-life. Facilitates transfer of chemicals through the stratum corneum with
OTC:VDRMLong
by Cryptocol
Finally!! FDA Number for Premature Ejaculation Drug IS IN! LOS ANGELES, CA--(Marketwired - June 27, 2017) - ViaDerma, Inc. (OTC PINK: VDRM), a specialty pharmaceutical company devoted to bringing new products to market, recently announced today that the Company has received its National Drug Code (NDC) 69006-010-00 from the Food and Drug Administration (FDA) for its new over the counter or OTC medication, Prolayed, a male genital desensitizer to delay onset of ejaculation. The company's FDA Registered Prolayed combines Lidocaine as the active ingredient with ViaDerma's proprietary transdermal delivery system. The new "OTC Drug" is now ready for sale. The Company's recent testing has proved to be successful. The market for Premature Ejaculation (PE) is estimated to be $1.3 billion in 2017. The Company's topical solution does not have to be ingested and processed through the body's internal organs. The Company believes there is a vast market for this type of non-orally ingested new product and should generate significant Company revenues in the near future. This is another product in the "Go to Market Strategies" pipeline. The Company already has located a suitable manufacturer and seeks distributors. The Company is continuing the completion of the labeling, quality control, marketing, and distribution now for several new products. Premature ejaculation sprays became available in the UK in last year in November, but men wishing to use it would have to visit their Doctor, who would then order the spray from a pharmaceutical company. Now, men can purchase the spray themselves directly from an online pharmacy. In other reported testing, the product works on 9 out of 10 men and can have them last twice as long during sexual intercourse. Research reports have found the premature ejaculation treatment market has been estimated to be approximately $1.3 Billion dollars for 2017, up from about $684 million dollars in 2010 based on the U.S. and European approval of several new products. Trends, Technologies & Opportunities Report for 2016-2020 with key vendors being Pfizer, Emcure, Eli Lilly. In Technavio's report, Global Premature Ejaculation Treatment Market for the 4-year period states that the analysts forecast for the global PE treatment market to grow at a CAGR of 9.65% during that period. Company Update The production of the Company's topical antibiotic is still on track and the Company is finalizing purchase orders for the product which should be shipped to distributors within the next few weeks. Also, the Company has had new inquiries from distributors in South Korea, and a meeting is scheduled in the first week of July to finalize a sales agreement. The lawsuit filed against the Company has been answered and the Company's legal counsel Austin Legal Group, from San Diego, has filed a motion to dismiss the plaintiffs' claims in Federal Court.
OTC:VDRMLong
by Cryptocol
MM's shaking out weak handsNothing new here, seen this time and time again with VDRM. Company gets good news and stock "tanks". Always rebounds and always comes back stronger. Chart is still strong looking and once we get serious volume rolling in again I think we skyrocket straight to a nickel. FDA approval could push this even further to dime land. We will see. Longs must be patient, good things will come, do not fall for the tricks and get ruined by dirty tactics. Long and strong. Millionaires will be made!
OTC:VDRMLong
by Cryptocol
FDA Approval "coming soon"From a post on ihub- an investor emailed investor relations and received this response $$$ to: info@viadermalicensing.com cc: sales@viadermalicensing.com subject: Update mailed-by: gmail.com Hello, I have a few questions: 1-Can we expect a PR with a FDA approval this week or next for your product for treating Premature Ejaculation? 2-Are sales rolling out this quarter for Viabecline? 3-Will the lawsuit be dropped or settled this quarter? Will ViaDerma prevail? 4-Hasn't the efficacy already been done for Viabecline? Why have you started a new independent study in Texas to prove Viabecline's efficacy in treating diabetic foot wounds? 5-How much revenue do you expect from the grass roots THC and non-THC Cannabinoids, both in a patch form, roll on and spray signed with the Canadian company? Are your plans to sell licensing agreements to major producers? Thank you ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ info@viadermalicensing.com 3:08 PM (17 hours ago) FDA approval is on track. No delays are expected. Stand by for updates on that Rollout is also still on time and should be out by the of the quarter (one month from now) We received a continuance to submit our reply to the lawsuit. That's usually pretty standard. We will report developments as they happen but we feel very strongly we will prevail. We cant say too much until after we file our official reply with the court Efficacy has been done but the reason for the independent study is to show we do it better. Can't answer any revenue guidance question yet until we release that to the public. Hopefully soon. Stay tuned for more news in the near future. We expect to report on some of these and other developments shortly. Thanks Investor Relations (310) 734 6111
OTC:VDRMLong
by Cryptocol
$OWCP Bullish Pennant Formation with Upcoming MJ Catalysts News ANNUAL REPORT CLARIFICATION FOR SHAREHOLDERS: 1) Page 5: Don't get confused by the OWCP already done Psoriasis study (where efficacy results are imminent) and next deeper and extended studies planned from April: "On February 1, 2017, following the very encouraging results that have been achieved at the mid-point of the Study, the Company determined to extend the size and scope of the Study for the purpose, among other things, of checking the biological markers that have been generated to date with respect to the treatment of psoriasis (proliferation/ inhibition and several interleukins). Despite extending its size and scope of the Study, the Registrant expects to compete the Study during the 2 nd or 3 rd quarters of 2017." The study already done is confirmed in page 36: "We have been conducting a study on the efficacy of the cannabinoid-based topical cream for the treatment of skin conditions generally and psoriasis specifically, which commenced in November, 2016 " While the extended study to start in April 2017 according to previous 8K is the safety phase and identification of biological markers useful to identify potential other application of the cream (Skin Cancer imo): "We started safety phase at the hospital by this month, April 2017, and already planning a unique multi-center efficacy study. This is the natural development of the next generation of safe and tested cannabinoids treatments" 2) Page 5-6: Multiple Myeloma Amazing News for Shareholders is here: "Dr. Leiba led our in vitro studies on the effect of a formulation comprised of Cannabidiol (CBD) and tetrahydrocannabinol (THC) on multiple myeloma cells studied outside their normal biological context. The results indicated a 100% mortality rate of myeloma cells in 80% of the cultured cells within a 24 to 48-hour period, and highlight the potential abilities of cannabis oil extract to fight multiple myeloma cancer cells. We believe that the results of this study indicate a potential to develop a more effective treatment for multiple myeloma than standard therapies." "Expect to submit a clinical trial protocol to the Israeli Institutional Review Board and received its approval to commence a clinical study" "Intend to commence a clinical study in the third quarter of 2017" 3) Notes on competition page 7: For Psoriasis they aim to attack Big Pharma market and they are well aware of current products and thier limitation: "The current common treatments for psoriasis include topical and systemic drugs, steroids, immunosuppressive drugs such as Cyclosporine A (by Novartis), methotrexate or MTX and biological drugs such as Enbrel (by Amgen), Amevive (by Biogen but whose patent expired in 2013) and Ustakinumabn (by Janssen Immunology)." This is excelent Marketing strategic approach; 4) Page 8: Provisional Patents are listed in report, can be downloaded through reference number and are real! They are extremely well written in a professional way and full of interesting claims: when needed (close to deadline) they will pay the service fees and transform them in Official US Permanent Patent; Why to do it before if the provisional is free of charge? Smart approach; 5) Page 12: CERTIFICATION and FDA approval all diligently work has been done according to standard: " Israel’s Ministry of Health, which regulates medical testing, has adopted protocols that correspond, generally, to those of the FDA and the EMA, making it comparatively straightforward for studies conducted in Israel to satisfy FDA and the European Medicines Agency requirements, thereby enabling medical technologies subjected to clinical trials in Israel to reach U.S. and EU commercial markets in an expedited fashion. Many members of Israel’s medical community have earned international prestige in their chosen fields of expertise and routinely collaborate, teach and lecture at leading medical centers throughout the world. Israel also has free trade agreements with the United States
OTC:OWCPLong
by StockGuild
$OWCP Why I'm Extremely Long on This $5.00 by EOMI was in on the initial run .0030 - .10 bought and sold from .10 - $3.00 bought and sold (both times sold too early) and now .50 - $5.00 Here's why: PROVISIONAL PATENTS TAKE ABOUT 8-12 MONTHS TO GET TURNED INTO APPROVED PATENTS. Here's the list of $OWCP Patents: 1) patentscope.wipo.int 2) patentscope.wipo.int 3) patentscope.wipo.int 4) patentscope.wipo.int 5) patentscope.wipo.int 6) patentscope.wipo.int 7) patentscope.wipo.int Also the Patent Document: www.docdroid.net FROM THE 8K ON APRIL 4TH: OWC Pharmaceutical Research Corp. ("OWC") is reporting the issuance on April 5, 2017 of the attached press release, announcing that as a result of the promising conclusions reported in its Form 8-K filed on March 20, 2017, the Company has received expressions of scientific and medical interest, world-wide, for its cannabinoid-based topical cream for treating psoriasis. OWCP has expanded the size and scope of its clinical studies and, as previously announced, anticipates that subject to pending regulatory approvals from applicable jurisdictions, the topical cream should be available for use by those who suffer from psoriasis in the near term. ALSO LETS NOT FORGET 4/20 In addition we have many news outlets covering MJ which is bringing it back into the light. CANADA LEGALIZING IT NATIONWIDE. Too many catalysts to cover. Once we break key resistance tomorrow we could see $2.00 by EOD
OTC:OWCPLong
by StockGuild
$ATTBF History Repeats Itself 2014 Run from .0125 to $2.85Remember the first MJ Rush in 2014? $ATTBF one of the few stocks HQ'ed in Canada but traded in America with its second symbol went from .0125 to $2.85 on Colorado recreationally legalizing MJ back in 2012 and the law was implemented that year and a few others legalized it recreationally and medically as well. Well now that beautiful rush has come full circle once again. Those states that legalized it that year implemented it last year and those profits will be on balance sheets this year, in addition Canada is going to approve recreationally Marijuana legally across their entire country on April 20th. With $ATTBF HQ'ed in Canada this is the green gold everyone will be waiting for. MJ stocks will shoot up, but MJ stocks from Canada will more than likely shoot even higher. $ATTBF has the best of both worlds, Bio and Medical Marijuana and other MJ products, a beautiful marriage of everything we love in both worlds. The chart and technical are primed for a beautiful run upwards. I would not say its outrageous to suggest a PPS target of $3.00 or more this time around. As can be seen, this stock has shown true strength and movement when it wants to.
OTC:ATTBFLong
by StockGuild
$ENDV Excellent Breakout Pattern ConfirmedBreakout past the 50DMA was a key point today. PARSAR flip Bolli and Ichimoku Cloud break. This move is mostly due to immense fundamentals at work and not an actual technical push, which is the best part, if you remember $OWCP this is similar in terms of fundamentals, but with much more potential and in term a much higher ROI. One of my 3 long term holds as of today. 1. Application for Orphan Drug Status Push 2. Preclinical Studies 3. Application for Uplistment 4. Debt being bought by the company and a interested major investor 5. Insider buying through multiple Form 4s 6. Multiple Patents for their Medical Technology
OTC:ENDVLong
by StockGuild
1
VDRM Brings in Ivan Klarich" ViaDerma, Inc. (OTC PINK: VDRM), a specialty pharmaceutical company devoted to bringing new products to market, recently announced today that the Company has hired Mr. Ivan Klarich, who is an expert in managing the launching of "Go to Market" strategies for new product compliance. The Company wants to avoid the pitfalls often found in the launching a new product or product line. The Company wants to assure a solid strategy behind the launch for the labeling, marketing and distribution. The "Quality Control" plan will assure the product meets strict guidelines, starting with the manufacturer all the way through to the point of purchase. The Company plans to continue to hire several experts in the specialty pharmaceutical field as the Company rolls out an aggressive growth plan for 2017 and the years ahead." Very excited for this PR and what it means for the long run for VDRM. Anyone who has been following my posts knows I'm very long long on this company in 2017. I think we may see a 20% green day today, but even if we continue to go back down a bit I have no worries and will continuing buying more. VDRM long and strong! Millionaires will be made
OTC:VDRMLong
by Cryptocol
Greatness Takes Time.I'm seeing some bashing of this company on a few other outlets. I think one thing new investors into VDRM need to realize is that greatness takes time. If you bought into it at 0.06-0.07 because somebody told you it was going to run to a $1 overnight, that's all on the trader and not on the stock. If you look at the chart, this is a very healthy company with a very healthy chart. Slow and steady is the way to go. This company is in store for greatness, and I do believe we see $1 in 2017/2018 however new traders need to realize that a jump from pennies to a dollar happens very rarely unless the company undergoes a R/S or has some suspicious activity going on with it. If you are newly invested into VDRM and are currently sitting at a loss or near a loss I encourage you to hold tight and be patient. if you sell without the intent to buy back in, I suggest you ignore this ticker for the next year or so. We will do great things, we have done great things, and great things will continue to happen slowly but surely with this stock. Millionaires will be made.
OTC:VDRMLong
by Cryptocol